Drug Topics met with Amanuel Kehasse, PharmD, PhD, to discuss the barriers surrounding biosimilar implementation in the prescription drug market.
Amanuel Y. Kehasse, PharmD, PhD
Advertisement
Amanuel Kehasse is the Director of Clinical Programs and Drug information at Clearway Health in Boston. Previously, he was Ambulatory Clinical Manager (Specialty Pharmacy) with Boston Medical Center (BMC). He has since delved into teaching as an Assistant Professor of Medicine at Boston University School of Medicine.
Articles by Amanuel Y. Kehasse, PharmD, PhD
Amanuel Kehasse, PharmD, PhD, explored reasons why patients and providers may be avoiding the implementation of biosimilar medications.
Advertisement
Latest Updated Articles
Q&A: Educating Patients, Providers to Increase Biosimilar Implementation | ASHP MidyearPublished: December 16th 2024 | Updated:
Gap in Biosimilar Knowledge Causes Barriers to Implementation | ASHP MidyearPublished: December 12th 2024 | Updated:
Advertisement
Advertisement
Trending on Drug Topics
1
Lower Baseline BMI Predicts Weight Loss At 6 Months With Liraglutide
2
Providers, Patients Show Favorable Perception of Remdesivir During COVID-19 Pandemic
3
How the Delinking Model Can Drive Transparency, Avoid PBM Manipulation | NCPA 2025
4
Pharmacies Should Be Proactive in Expanding Clinical Services, Reimbursement Pathways | NCPA 2025
5
